Results 331 to 340 of about 1,602,934 (395)
This manuscript describes the scope of implementation and impact of a regulatory agency‐qualified panel of six urine biomarkers on drug development, the process for which was conducted and funded by the Critical Path Institute, the Foundation for the National Institutes of Health, and the United States Food and Drug Administration.
Tanja S. Zabka +7 more
wiley +1 more source
Cytotoxicity and virulence attributes of <i>Pseudomonas aeruginosa</i> isolates from case reports of patients with necrotizing pneumonia. [PDF]
Bolig TC +13 more
europepmc +1 more source
Analysis of infection-related adverse events induced by proton pump inhibitors based on the FAERS and JADER databases. [PDF]
Hu S, Yu H, Liu Z.
europepmc +1 more source
Lung ultrasound alterations six months after COVID-19 pneumonia: a descriptive study. [PDF]
Navarro-Romero F +4 more
europepmc +1 more source
Letter to the editor regarding: 'risk factors for bronchiolitis obliterans in children with community-acquired pneumonia'. [PDF]
Özkaya AK.
europepmc +1 more source
Differential diagnosis in patients with both features of pneumonia and pulmonary edema on chest computed tomography. [PDF]
Lee HJ +11 more
europepmc +1 more source
Diagnosis, treatment, and monitoring of cytomegalovirus pneumonia in a hematopoietic stem cell transplantation child. [PDF]
Xuan F +6 more
europepmc +1 more source

